AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca said the "cornerstone" of the commitment would be a new weight management production facility for its oral GLP-1 drug.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
